S

Sanofi

Global pharma company; vaccines and R&D

Medical Information Writer

Full-TimeUpdated on 10/23/2026Deadline 10/31/26
No salary listed
Mid
Master's, MBA
Hyderabad, Telangana, India
In Person
Content & WritingTechnical Writing

About the job

Requirements
  • 2–3 years of experience in medical writing for the pharmaceutical or healthcare industry, or equivalent experience in a clinical setting.
  • At least 1–2 years of direct medical information experience in a pharmaceutical company.
  • Stakeholder management, communication skills, and the ability to work independently and within a team environment.
  • Medical operational excellence, time management, and risk management skills.
  • Excellent technical medical editing and writing skills.
  • Knowledge of literature evaluation and multilevel response development.
  • An advanced degree in life sciences, pharmacy, a similar discipline, Master of Science, MBA, or equivalent.
  • Excellent spoken and written knowledge of English.
Responsibilities
  • Conduct literature searches and reviews, and extract and summarize complex data from scientific literature.
  • Generate evidence-based, accurate, current, and fair-balanced data summaries to create and maintain scientific response documents for products in designated therapeutic areas.
  • Adapt global scientific response documents for assigned countries.
  • Develop responses to escalated inquiries for assigned countries.
  • Develop contributions to U.S. New Drug Application Annual Reports.
  • Contribute to U.S. compendia reviews.
  • Execute medical information projects after conceptualization, with guidance from experienced team members or managers.
  • Complete tasks with resolve and urgency under supervisor guidance, participate in cross-functional project teams as needed, and complete assigned projects on schedule.
  • Develop and maintain therapeutic-area expertise.
  • Conduct quality checks on peer outputs when business needs require.
  • Collaborate with Global Medical Information teams to execute content plans.
  • Maintain effective relationships with medical-scientific community stakeholders within the allocated global business unit and product to develop medical information content as required.
  • Interact effectively with stakeholders in medical and pharmacovigilance departments.
  • Assist other medical information writers in developing knowledge and sharing expertise.
  • Provide scientific response documents, U.S. New Drug Application Annual Reports, and U.S. compendia reviews according to agreed timelines and quality standards.
  • Work with minimum supervision to conduct data sanity checks and produce error-free medical information project outputs for supported countries.
  • Assist the assigned medical information team in conducting a comprehensive medical writing needs analysis.
  • Implement relevant elements of content plans and associated activities for assigned countries.
  • Work with selected regional vendors to deliver required deliverables according to the defined process.
  • Help the manager design an overall plan of action based on end-customer feedback and improve course content and delivery.
  • Work closely with regional and area medical teams to identify medical writing needs and assist in developing assigned deliverables.
  • Liaise with the Medical department to prepare relevant and customized deliverables.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...